Roots Analysis

FEBRUARY 18, 2022

Over time, many research studies have shown that myeloid cells can interact with the immune system and aid in generating an appropriate anti-tumor immune response. The key focus of these studies is on the development of anti-tumor therapeutics. CLINICAL TRIALS EVALUATING MYELOID CELLS TAREGTING THERAPEUTICS.

Drug Delivery Systems 52

Drug Delivery Systems Immune Response Clinical Trials Clinical Trials 52

Roots Analysis

MARCH 3, 2022

Since the approval of Soliris® in 2007, an anti-C5 antibody, the field of complement drug discovery has gained significant attention. Currently, nine complement therapeutics are commercially available, while around 190 molecules are under development for various disease indications. Next Generation Complement Therapeutics. Web: [link].

Drug Delivery Systems 52

Drug Delivery Systems Marketing Immune Response Dermatology 52

Roots Analysis

MAY 21, 2024

Over the last decade, one of the major challenges faced by pharmaceutical companies across the globe is low drug solubility. In fact, it has been observed that around 40% of the pharmaceutical drugs approved by regulatory organizations exhibit poor bioavailability / solubility.

Drug Delivery 40

Drug Delivery Drugs Gene Therapy Bioavailability 40

Drug Discovery World

FEBRUARY 5, 2024

DDW’s Megan Thomas spoke to experts from the drug discovery industry about their predictions on what 2024 holds for our sector. Greg Rossi, Senior Vice President, Head of Oncology, AstraZeneca Europe & Canada “Advances in science and technology have brought us to an incredible inflection point in cancer management and healthcare delivery.

Research 116

Research Gene Sequencing Drug Delivery Systems Trials 116

STAT News

NOVEMBER 3, 2022

The companies allege Moderna’s vaccine uses their technology for a drug-delivery system without permission. Citing The single-dose vaccine candidate is a combination of Pfizer’s mRNA-based flu shot and the Omicron-tailored Covid-19 booster shot developed by both companies.

Vaccination 97

Vaccination Vaccine Drug Delivery Systems Sales 97

Pharmaceutical Technology

APRIL 24, 2023

In 1974, Dr. Robert Langer was part of the first cohort of researchers to begin nanoparticle research , as his lab at Cornell University developed tiny particles to deliver large molecules for angiogenesis. Since then, the drug has been used off-label in breast cancer and other types of cancer.

Drug Delivery 147

Drug Delivery Vaccination Vaccine Research 147